Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

Undefined
7
Average: 7 (1 vote)

Nat Clin Pract Oncol. 2008 Aug;5(8):487-91. Epub 2008 Jun 17.

 

Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

 


 

Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA. splotkin@partners.org

BACKGROUND: A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation.

INVESTIGATIONS: Medical and neurological examination, MRI scan of the brain and spinal cord, pure-tone audiometry, NU-6 monosyllabic word test with phoneme scoring, City University of New York topic-related sentences test, noise/voice test of minimal auditory capability battery.

DIAGNOSIS: Progressive neurofibromatosis-type-2-related vestibular schwannomas.

MANAGEMENT: Annual cranial MRI and audiology, surgical resection of right vestibular schwannoma, high-power behind-the-ear hearing aid, erlotinib therapy for progressive left vestibular schwannoma.